Understanding Oral Candidiasis and Candida albicans
Oral thrush is caused by overgrowth of Candida albicans, a fungus that normally exists in your mouth at low levels. Candida is part of your normal oral flora, kept in check by competing bacteria and your immune system. When conditions change—allowing Candida to proliferate—it transforms from a commensal organism to a pathogenic infection.
Candida albicans is the primary cause of oral candidiasis, though other species (C. glabrata, C. tropicalis) occasionally cause infection. The organism produces tissue-damaging enzymes and produces ethanol that further damages oral tissue.
Risk Factors and Predisposing Conditions
Immunosuppression is the primary risk factor for thrush. HIV/AIDS patients with CD4 counts below 50 cells/microL have very high thrush risk. Cancer patients undergoing chemotherapy develop immunosuppression-related thrush. Transplant recipients on immunosuppressive medications are at increased risk.
Broad-spectrum antibiotic use eliminates normal bacterial flora that compete with Candida, allowing overgrowth. Thrush commonly develops during or shortly after antibiotic courses, particularly with prolonged oral antibiotic therapy.
Corticosteroid use, particularly inhaled corticosteroids (for asthma, COPD), increases thrush risk. Inhaled steroids deposit directly in the mouth, reducing local immune function.
Denture wear increases thrush risk by creating an occlusive environment favorable to Candida growth. Poor denture hygiene (inadequate cleaning or extended wear without removal) is particularly problematic.
Dry mouth (xerostomia) from any cause predisposes to thrush. Without adequate saliva's antimicrobial properties, Candida overgrows readily.
Poor oral hygiene and heavy plaque accumulation increase thrush risk.
Diabetes, particularly poorly controlled diabetes, increases thrush risk through elevated glucose levels in saliva (providing a bacterial substrate) and impaired immune function.
Poor nutrition, particularly zinc deficiency, impairs immune response to Candida.
Clinical Presentation of Thrush
The most common presentation is white patches (plaques) in the mouth that appear as a thick white coating on the tongue, palate, gingival tissue, or buccal mucosa (inner cheeks). These patches cannot be wiped off (though they may be slightly removable with vigorous rubbing).
Beneath the white patches, the tissue is red and may be bleeding. The patches may extend throughout the mouth, affecting multiple surfaces.
Patients often report a burning sensation or altered taste. Some describe a metallic taste. Pain may range from mild to severe, particularly when eating spicy or acidic foods.
The red, raw appearance beneath plaques may be the only presentation, without prominent white patches. This erythematous form can be subtle and easily missed.
Angular cheilitis (cracks and erythema at the mouth corners) is sometimes associated with oral thrush, though it has multiple causes.
In severe cases, thrush extends into the esophagus (esophageal candidiasis), causing difficulty or pain with swallowing. This is more common in severely immunocompromised patients and warrants systemic antifungal treatment.
Diagnosis of Oral Candidiasis
Your dentist typically diagnoses thrush clinically based on appearance and associated risk factors. The white patches with underlying erythema are characteristic.
Confirmatory testing involves:
- Oral rinse culture: Swishing with sterile water and collecting organisms in culture
- Smear preparation: Brushing or swabbing the lesion and examining under microscope for Candida pseudohyphae
- KOH (potassium hydroxide) mount: Preparation allowing visualization of Candida filaments
Culture can identify the Candida species and antifungal susceptibility, important if treatment fails.
Histopathology (tissue biopsy) is rarely necessary unless diagnosis is uncertain or lesions are unusually extensive.
Treatment of Uncomplicated Oral Candidiasis
Topical antifungal therapy is first-line for localized oral thrush. These include:
Nystatin: Available as suspension (swish and swallow), pastilles, or cream. Suspension is applied topically to affected areas multiple times daily. Pastilles are slowly dissolved in the mouth. Treatment typically lasts 1-2 weeks.
Clotrimazole: Available as troches (lozenges) that dissolve slowly in the mouth, allowing sustained antifungal contact. Used 3-5 times daily for 7-14 days.
Miconazole: Available as gel or spray applied topically.
These topical agents are effective for localized thrush but don't achieve sufficient systemic levels to treat esophageal candidiasis.
Systemic antifungal therapy is used when:
- Topical therapy fails
- Esophageal involvement is suspected or confirmed
- Patient cannot tolerate topical agents (nausea, swallowing difficulty)
- Immunocompromised patient with severe infection
Fluconazole is typically used at 100-200 mg daily for 7-14 days. This achieves good oral tissue penetration and esophageal penetration.
Other systemic options include itraconazole and posaconazole for resistant cases.
Treatment Resistance and Antifungal-Resistant Candida
Some patients, particularly those with prolonged immunosuppression, develop resistant Candida albicans or infection with inherently resistant species like C. glabrata or C. auris. These resistant infections don't respond to standard azole antifungals (fluconazole, itraconazole).
Resistant infections may require amphotericin B (echinocandins like caspofungin) for adequate treatment. Infectious disease consultation is often necessary for resistant cases.
Addressing Underlying Risk Factors
Successful thrush treatment requires addressing predisposing factors. Improving denture hygiene—removing and cleaning the denture daily with antifungal denture cleaners—is essential. Removing the denture at night allows tissue recovery.
Discontinuing systemic antibiotics (if possible) allows normal bacterial flora to recover and outcompete Candida.
Optimizing inhaled corticosteroid technique—rinsing mouth after use, using a spacer to reduce oral deposition—reduces thrush risk.
Improving oral hygiene through thorough brushing and flossing removes plaque and reduces Candida substrates.
Treating xerostomia with saliva substitutes or stimulants reduces thrush risk.
Controlling blood glucose in diabetic patients improves immune response to Candida.
Prevention of Recurrent Thrush
In immunocompromised patients with frequent thrush recurrence, suppressive antifungal therapy (fluconazole 100-200 mg daily) is often recommended. This prevents recurrent infections but must be balanced against resistance development risk.
Prophylactic antifungal therapy is particularly important in HIV patients with CD4 counts below 50 cells/microL.
Patients on chronic corticosteroid inhalation therapy may benefit from prophylactic fluconazole or improved inhaler technique to minimize oral steroid deposition.
Special Considerations in Immunocompromised Patients
Severely immunocompromised patients (HIV with low CD4, transplant recipients, chemotherapy patients) with oral thrush are at high risk for esophageal extension and disseminated candidiasis. These patients require systemic antifungal therapy and closer monitoring.
Immune reconstitution after antiretroviral therapy initiation in HIV patients or after reducing immunosuppressive medications in transplant patients typically resolves thrush.
Prognosis
Uncomplicated oral thrush in immunocompetent patients typically resolves within 1-2 weeks of appropriate treatment. Recurrence is uncommon if predisposing factors are addressed.
Immunocompromised patients often experience recurrent thrush despite treatment if underlying immunosuppression isn't addressed. In these patients, infection management focuses on control rather than cure, with suppressive therapy preventing symptomatic episodes.
Contact your dentist if you develop oral white patches, burning mouth sensations, or suspect thrush. Early diagnosis and treatment prevent discomfort and serious complications like esophageal involvement.